But buyers should tread carefully with low-beta plays, even though they tend to have lower risk profiles relative to other equities, market commentators told CNBC's"I probably wouldn't be that inclined to use individual stocks as market hedges at this time," said Katie Stockton, founder and managing partner of Fairlead Strategies.
"Clorox does stand out to me from a technical perspective as having some upside potential," she said, referencing its chart. Clorox closed at $174.90 on Monday, up nearly 1%, after reaching a new 52-week high earlier in the session. Stockton added that Clorox's relative strength, or performance vis-a-vis benchmarks like the S&P, "has certainly improved."
Quint Tatro, founder and chief investment officer of Joule Financial, wasn't a fan of any of the above names.